EDGAR MUSNGI: Open Payments
NPI 1871523563 · TORRANCE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,210 in 61 payments from 18 companies in 2025. Trend: 2023 $527 · 2024 $856 · 2025 $1,210
Food & beverage: $1,210
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 12 | $181 |
| AKEBIA THERAPEUTICS INC | 7 | $160 |
| Novo Nordisk Inc | 10 | $141 |
| Novartis Pharmaceuticals Corporation | 5 | $119 |
| Amgen Inc. | 6 | $119 |
| OPKO Pharmaceuticals, LLC | 3 | $58 |
| AstraZeneca Pharmaceuticals LP | 3 | $57 |
| Apellis Pharmaceuticals, Inc. | 2 | $55 |
| SCPHARMACEUTICALS INC. | 2 | $51 |
| GENZYME CORPORATION | 2 | $48 |
Products named: Vafseo, KRYSTEXXA, Ozempic, RAYALDEE, FARXIGA, Empaveli, FUROSCIX, FABRAZYME.
Industry payments across CA — which companies pay providers there.
